Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 4.69 is 44% below its 3-year average of 8.35, near the low end of its 3-year range (0.00–90.42).
As of the fiscal period ended Tuesday, June 30, 2026. 43.51% below its 12-month average of 8.31.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 4.69.
CURRENT RATIO
4.69
CURRENT RATIO AVG TTM
8.31
CURRENT RATIO AVG 3Y
9.11
CURRENT RATIO AVG 5Y
N/A
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-43.51%
CURRENT VS 3Y AVG
-48.45%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.51
median of 734 covered companies
CURRENT VS SECTOR MEDIAN
+33.74%
vs the sector median at left
BridgeBio Oncology Therapeutics Inc.
Market Cap
$289.99M
Current Ratio
4.69
TTM Avg
8.31
3Y Avg
9.11
5Y Avg
N/A
Market Cap
$288.14M
Current Ratio
6.63
TTM Avg
6.50
3Y Avg
6.00
5Y Avg
4.95
Market Cap
$294.13M
Current Ratio
4.70
TTM Avg
5.10
3Y Avg
7.75
5Y Avg
8.34
Market Cap
$285.37M
Current Ratio
19.48
TTM Avg
1.73
3Y Avg
4.11
5Y Avg
4.35
Market Cap
$283.44M
Current Ratio
31.35
TTM Avg
25.02
3Y Avg
20.04
5Y Avg
16.03
Market Cap
$300.93M
Current Ratio
34.00
TTM Avg
44.34
3Y Avg
25.02
5Y Avg
19.51
Market Cap
$277.46M
Current Ratio
4.85
TTM Avg
6.69
3Y Avg
6.56
5Y Avg
6.64
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BridgeBio Oncology Therapeutics Inc. (BBOT) | $289.99M | 4.69 | 8.31 | 9.11 | N/A |
| Abeona Therapeutics Inc. (ABEO)vs › | $288.14M | 6.63 | 6.50 | 6.00 | 4.95 |
| Standard BioTools Inc. (LAB)vs › | $287.22M | 9.10 | 4.95 | 4.04 | 3.29 |
| Larimar Therapeutics, Inc. (LRMR)vs › | $294.13M | 4.70 | 5.10 | 7.75 | 8.34 |
| Indaptus Therapeutics, Inc. (INDP)vs › | $285.37M | 19.48 | 1.73 | 4.11 | 4.35 |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $283.44M | 31.35 | 25.02 | 20.04 | 16.03 |
| Aurora Cannabis Inc. (ACB)vs › | $279.05M | 5.36 | 5.13 | 3.92 | 3.90 |
| Benitec Biopharma Inc. (BNTC)vs › | $300.93M | 34.00 | 44.34 | 25.02 | 19.51 |
| Fate Therapeutics, Inc. (FATE)vs › | $277.46M | 4.85 | 6.69 | 6.56 | 6.64 |
| SAB Biotherapeutics, Inc. (SABS)vs › | $277.05M | 9.22 | 6.22 | 4.84 | 4.06 |
Current Ratio
4.69
Quick Ratio
4.69
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 4.69 |
| 2026-03-31 | 6.16 |
| 2025-12-31 | 12.14 |
| 2025-09-30 | 13.33 |
| 2025-06-30 | 5.22 |
| 2025-03-31 | 5.87 |
| 2024-12-31 | 10.40 |
| 2024-09-30 | 16.12 |
| 2024-06-30 | 26.23 |
| 2024-03-31 | 90.42 |
| 2023-12-31 | 0.00 |
| 2023-09-30 | 0.00 |
| 2022-12-31 | 0.00 |
